KC
BIOT

Kryger Capital’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Kryger Capital’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-844,965
Closed -$8.33M – 237
2022
Q1 		$8.33M Buy
844,965
+171,411
+25% +$1.69M 0.48% 38
2021
Q4 		$6.63M Buy
+673,554
New +$6.61M 0.37% 51

Other funds holding BIOT

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
CM
Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return
RA
RiverPark Advisors New York $219M AUM 14.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Kryger Capital's BIOT Position: Q2 2022 in Review

Kryger Capital sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q2 2022, closing a stake of 844,965 shares — an estimated $8.33M sold.

Kryger Capital first reported a position in BIOT in Q4 2021 and held it in 2 quarters. The position peaked at $8.33M in Q1 2022. 67 funds tracked by Wall St. Rank hold BIOT as of Q2 2022.

  • Kryger Capital reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • Kryger Capital sold 844,965 Biotech Acquisition Company Class A Ordinary Shares shares in Q2 2022, an estimated $8.33M.
  • Kryger Capital first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2021 and held it in 2 quarters.
  • Kryger Capital's Biotech Acquisition Company Class A Ordinary Shares position peaked at $8.33M in Q1 2022.
  • 67 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q2 2022.

Based on Kryger Capital's 13F filing for Q2 2022, filed 15 Aug 2022.